Dominick Colangelo
Chief Executive Officer presso VERICEL CORPORATION
Patrimonio netto: 10 M $ in data 30/04/2024
Posizioni attive di Dominick Colangelo
Società | Posizione | Inizio | Fine |
---|---|---|---|
VERICEL CORPORATION | Director/Board Member | 01/03/2013 | - |
Chief Executive Officer | 01/03/2013 | - | |
President | 01/03/2013 | - | |
TREVI THERAPEUTICS, INC. | Director/Board Member | 29/06/2020 | - |
Independent Dir/Board Member | 29/06/2020 | - |
Storia della carriera di Dominick Colangelo
Precedenti posizioni note di Dominick Colangelo
Società | Posizione | Inizio | Fine |
---|---|---|---|
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Director/Board Member | 23/02/2011 | 15/05/2012 |
Chief Executive Officer | 01/12/2008 | 15/05/2012 | |
President | 01/12/2008 | 15/05/2012 | |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Chief Operating Officer | 01/01/2005 | 11/12/2008 |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Chief Investment Officer | - | 07/12/2005 |
Private Equity Investor | - | 07/12/2005 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/1995 | - |
Formazione di Dominick Colangelo
State University of New York at Buffalo | Undergraduate Degree |
Duke University School of Law | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 2 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
VERICEL CORPORATION | Health Technology |
TREVI THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Commercial Services |
LV Management Group, LLC
LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Promedior, Inc.
Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Dominick Colangelo
- Esperienza